Raab G Gregory, Parr David H
Raab & Associates, Inc., North Bethesda, MD 20852-4328, USA.
J Am Coll Radiol. 2006 Sep;3(9):694-702. doi: 10.1016/j.jacr.2006.02.005.
Although reimbursement shapes medical practice, it is hard to get a handle on this issue because reimbursement requirements seem to change and evolve over time, and different insurers approach it in different ways for different technologies. This paper and the 2 that follow attempt to explain the reimbursement challenges facing new medical device technology. This first paper addresses the particular characteristics of medical device innovation and explains how they complicate the technology assessment process. It also notes the importance of codes as a means to identify new technologies and procedures, citing some issues that affect technology adoption. The subsequent papers delve into specific coverage and payment matters affecting medical devices. The perspective presented in these papers is that of a medical device manufacturer, and the focus tends to be on Medicare, given the size of this insurance program and its impact on the US health care system, but the issues that are raised affecting medical innovation can be extended to all payers.
尽管报销方式塑造了医疗实践,但由于报销要求似乎会随着时间的推移而变化和演变,而且不同的保险公司对不同技术的处理方式也不同,因此很难解决这个问题。本文以及接下来的两篇文章试图解释新医疗设备技术所面临的报销挑战。第一篇文章阐述了医疗设备创新的特殊特征,并解释了这些特征如何使技术评估过程变得复杂。文章还指出了代码作为识别新技术和程序的一种手段的重要性,并列举了一些影响技术采用的问题。随后的文章深入探讨了影响医疗设备的具体覆盖范围和支付问题。这些文章所呈现的观点是医疗设备制造商的观点,鉴于医疗保险计划的规模及其对美国医疗保健系统的影响,重点往往放在医疗保险上,但所提出的影响医疗创新的问题可以扩展到所有支付方。